Standards & Transparency: An Evidence Guide to What the Supplement Industry Owes You

The supplement market is, by design, difficult to navigate. Labels carry authorised health claims written in language so hedged they communicate almost nothing. Dosages are buried in proprietary blends. Studies cited in marketing copy are frequently funded by manufacturers, conducted on populations bearing no resemblance to the buyer, or simply misrepresented. If you are a research-driven adult who has spent any time trying to evaluate a supplement stack, you will have encountered all three.

This guide exists to give you a working framework for reading supplement evidence critically — not to dismiss the category, but to engage with it on honest terms. I will walk through how health claims are regulated in the UK and EU, what the hierarchy of evidence actually means in a supplement context, why dose transparency matters more than ingredient lists, and where the legitimate science sits relative to the marketing noise. I will also explain what KōJō does differently and why, because if I am going to write about standards, I should be prepared to be held to them.

The short version: the gap between what is claimed and what is proven in the supplement industry is wide. Closing it requires understanding regulatory frameworks, reading primary literature, and demanding that manufacturers publish their formulations in full — doses and all.

How Health Claims Actually Work in the UK and EU

The most important regulatory instrument governing supplement health claims in the UK and EU context is Regulation (EC) No 1924/2006, the Nutrition and Health Claims Regulation. Post-Brexit, the UK retained a version of this framework, and the European Food Safety Authority (EFSA) continues to be the scientific body whose opinions carry the most weight in European markets.

EFSA's process is worth understanding in detail, because it is considerably more rigorous than most consumers realise — and considerably more rigorous than most supplement marketing implies. When a manufacturer wishes to use a health claim, they must submit a dossier of evidence to EFSA's Panel on Nutrition, Novel Foods and Food Allergens (NDA). The panel evaluates whether the evidence is sufficient to establish a cause-and-effect relationship between the nutrient or substance and the claimed health outcome, at the dose specified, in the target population.

The bar is not trivial. EFSA has rejected the majority of health claim applications it has received. A recent example: EFSA evaluated a health claim application related to creatine and improvement in cognitive function, and its published opinion is a model of scientific rigour — examining the totality of evidence, the specificity of the claim, and whether the dose tested in trials corresponds to the dose in the product. Turck 2024 The same level of scrutiny was applied to a claim submitted for a specific ham product related to LDL-cholesterol and blood pressure — an application that illustrates how the framework applies to food products generally, not just isolated nutrients. Turck 2024

What this means practically: if a supplement label carries an authorised EFSA health claim, that claim has survived independent scientific scrutiny. If it carries language that sounds like a health claim but is not drawn from the authorised register — "supports your wellbeing", "for active lifestyles" — it has not. The distinction matters enormously.

The EFSA NHC register approves the wording "Vitamin C contributes to normal collagen formation for the normal function of skin" and "Vitamin D contributes to the normal function of the immune system." These are precise, evidence-grounded statements. They are also, notably, modest. That modesty is a feature, not a failure.

The Hierarchy of Evidence: Why Not All Studies Are Equal

The phrase "clinically proven" appears on supplement packaging with a frequency that bears no relationship to the quality of the evidence behind it. A single open-label pilot study with twelve participants, funded by the manufacturer, conducted over four weeks, does not constitute clinical proof of anything. It is a signal worth investigating further — nothing more.

The hierarchy of evidence in nutritional science runs roughly as follows, from weakest to strongest: mechanistic studies and cell-line data; animal studies; observational human studies; uncontrolled human trials; randomised controlled trials (RCTs); systematic reviews and meta-analyses of RCTs. Each step up the hierarchy controls for more sources of bias. Each step is also harder and more expensive to conduct, which is precisely why the supplement industry disproportionately cites the lower rungs.

A useful illustration of what rigorous design looks like: a 2023 head-to-head trial published in the Journal of the American College of Cardiology compared low-dose rosuvastatin, placebo, and a range of dietary supplements on lipid and inflammatory biomarkers. The supplements tested — including fish oil, cinnamon, garlic, and others — showed no significant LDL-lowering effect compared to placebo. The statin did. Laffin 2023 This is the kind of direct comparative evidence that is almost never commissioned by supplement manufacturers, for obvious reasons.

Similarly, a systematic review and meta-analysis of Ashwagandha supplementation for anxiety and stress found that while some RCTs reported positive outcomes, the methodological quality of the included trials was variable and the evidence base was insufficient to draw firm conclusions. Akhgarjand 2022 This does not mean Ashwagandha is ineffective — it means the evidence, at the time of that review, did not meet the standard required to make confident claims.

The honest position for any supplement manufacturer is to represent the evidence at the level it actually occupies in this hierarchy. When the evidence is preliminary, say so. When it is robust, cite the specific trials. When it does not exist, do not imply that it does.

Dose Transparency: The Single Most Ignored Standard

Ingredient lists are legally required. Doses are not — at least not individually, when ingredients are grouped into a proprietary blend. This regulatory gap is exploited routinely. A product may list ten ingredients, declare a total blend weight of 800mg, and leave the consumer entirely unable to determine whether any individual ingredient is present at a dose that has ever been tested in a human trial.

This matters because dose is not a detail. It is the mechanism. The same compound at 50mg and 500mg may have entirely different physiological effects — or no effect at all at the lower dose. Vitamin C at 500mg, for example, is a meaningfully different intervention from Vitamin C at 30mg, even though both products can legally claim "contains Vitamin C." KōJō Daily Formula includes Vitamin C at 500mg — a dose consistent with the range used in the trials that informed EFSA's authorised claims.

The olive oil polyphenol literature provides another instructive example. EFSA's authorised health claim for olive polyphenols specifies a minimum daily intake of 5mg of hydroxytyrosol and its derivatives. Research on extra virgin olive oil shelf-life and polyphenol stability has examined precisely how these compounds degrade over time and under different storage conditions — because the dose at the point of consumption, not at the point of manufacture, is what determines whether the claimed effect is plausible. Mancebo-Campos 2023 This kind of dose-level thinking is absent from most supplement formulation discussions.

The functional foods literature has begun to formalise this. A 2025 review in Nutrients examining functional foods through the lens of EFSA, FDA, and WHO frameworks emphasised that bioactive components must be present at physiologically relevant concentrations to confer the benefits attributed to them — and that the evidence base must be evaluated at the dose actually delivered. Fekete 2025

Full dose transparency — every ingredient, every dose, published on the label and on the product page — is not a marketing differentiator. It is a minimum standard. Any manufacturer unwilling to publish their full formulation is, implicitly, asking you to trust them rather than evaluate them. That is not a reasonable ask.

Conflict of Interest and Funding Bias in Nutritional Research

The relationship between industry funding and study outcomes in nutritional science is well-documented and uncomfortable. Manufacturer-funded trials are systematically more likely to report positive results than independently funded trials examining the same interventions. This is not always a matter of fraud — it operates through subtler mechanisms: selective outcome reporting, choice of comparator, duration of follow-up, population selection, and the straightforward fact that negative trials are less likely to be submitted for publication.

The implication for consumers is that a manufacturer citing "ten clinical studies" in support of their product has told you almost nothing useful unless you know who funded those studies, what outcomes were pre-registered, whether the full data were published, and whether the dose and population match your own situation.

This is not a counsel of despair. Independent systematic reviews exist precisely to aggregate and quality-assess the available evidence, controlling for funding bias where possible. Cochrane reviews, EFSA opinions, and meta-analyses published in peer-reviewed journals with declared conflicts of interest are more reliable than any single manufacturer-funded trial. The NMN literature provides a useful case study: a 2023 randomised, double-blind, placebo-controlled trial in healthy middle-aged adults found that NMN supplementation increased NAD+ concentrations in a dose-dependent manner, with an acceptable safety profile — but the authors were appropriately cautious about extrapolating from biomarker changes to clinical outcomes. Yi 2023 That caution is what honest science looks like.

Probiotic research faces similar challenges. A 2019 RCT examining probiotic Bifidobacterium strains and galactooligosaccharides found improvements in intestinal barrier function in obese adults, but noted that synbiotic combinations did not produce additive effects — a finding that complicates the common marketing claim that "more is better" in probiotic formulation. Krumbeck 2019

The standard I apply at KōJō is straightforward: I cite the primary literature, I disclose when evidence is preliminary, and I do not commission studies designed to produce favourable outcomes. If the evidence for an ingredient is weak, I either do not include it or I say clearly that it is included for a mechanistic rationale rather than established clinical proof.

Bioavailability: The Gap Between Label and Absorption

A compound present on a label is not necessarily a compound absorbed by the body. Bioavailability — the proportion of an ingested substance that reaches systemic circulation in an active form — varies enormously by compound, by formulation, by co-ingested nutrients, and by individual physiology. A supplement that ignores bioavailability in its formulation is, at best, leaving efficacy on the table. At worst, it is charging a premium for compounds that pass through without meaningful absorption.

Magnesium is a well-studied example. Magnesium oxide, the cheapest and most commonly used form, has a fractional absorption rate of roughly 4% in some studies — meaning the vast majority of the dose is excreted. Magnesium bisglycinate, a chelated form, demonstrates substantially higher absorption in comparative studies. KōJō Daily Formula uses Magnesium Bisglycinate at 1000mg (delivering 200mg elemental magnesium) — a form chosen specifically for its bioavailability profile, not for cost minimisation.

Zinc bisglycinate, similarly, is a chelated form with superior absorption characteristics compared to zinc oxide or zinc sulphate. KōJō uses Zinc Bisglycinate at 53mg (delivering 16mg elemental zinc). The distinction between total dose and elemental dose is itself a transparency issue: a label that states "zinc 53mg" without specifying elemental content is technically accurate but practically misleading.

The folate literature illustrates a related point about form. Folic acid, the synthetic form used in most supplements, requires enzymatic conversion to the active form (5-methyltetrahydrofolate) — a conversion that is impaired in individuals with MTHFR polymorphisms. Research examining folate metabolism gene polymorphisms in the context of supplementation outcomes has confirmed that form matters, not just dose. Zhang 2025 KōJō uses active folate (as methylfolate) at 400mcg for precisely this reason.

Ubiquinol, the reduced form of CoQ10, has superior bioavailability compared to ubiquinone in older adults, whose capacity to convert ubiquinone to ubiquinol declines with age. KōJō includes Ubiquinol at 100mg — not ubiquinone. These are not marketing distinctions. They are formulation decisions with direct implications for whether the compound in question reaches the tissue it is intended to reach.

What "Evidence-Led" Actually Requires

The phrase "evidence-led" has been adopted by enough supplement brands to have become nearly meaningless. I want to be specific about what I think it requires, because vagueness here is its own form of dishonesty.

Evidence-led formulation means: every ingredient is included because there is a plausible biological mechanism supported by human trial data at the dose used, or because EFSA's authorised health claim framework has validated the claim at that dose, or both. It does not mean including an ingredient because it appeared in a single rodent study, or because it is fashionable in the category, or because a competitor uses it.

Evidence-led communication means: representing the strength of the evidence accurately, distinguishing between what is established and what is preliminary, citing primary literature rather than secondary summaries, and updating claims when new evidence changes the picture.

Evidence-led transparency means: publishing the full formulation with every dose, declaring any conflicts of interest, and making it possible for a reader with access to PubMed to independently verify every claim made.

The functional foods framework described by international bodies including EFSA, FDA, and WHO requires that bioactive components be present at physiologically relevant concentrations with a documented mechanism of action. Fekete 2025 That is the standard I apply to KōJō's formulation. It is also the standard I think every supplement consumer should apply when evaluating any product.

The dietary fibre literature offers a useful parallel. Decades of research have established the relationship between fibre intake and cardiovascular and metabolic outcomes, but the evidence is strongest for specific types of fibre at specific doses — not for "fibre" as an undifferentiated category. Stephen 2018 The same specificity applies to every nutrient category. "Contains antioxidants" is not a claim. "Contains 200mg Grape Seed Extract delivering oligomeric proanthocyanidins at a dose consistent with the range studied in human trials" is approaching one.

The Problem with Proprietary Blends and "As-Studied" Claims

One of the more sophisticated forms of opacity in supplement marketing is the "as-studied" claim — the practice of citing a trial conducted on a specific branded ingredient at a specific dose, while using a different dose (almost always lower) in the actual product. The ingredient name may be identical. The dose is not. The consumer, unless they read the original trial, has no way of knowing.

This is compounded by the proprietary blend problem. When multiple ingredients are grouped under a single blend weight, the manufacturer can technically include a trademarked ingredient "as studied" while contributing only a fraction of the studied dose — the remainder of the blend weight being filled with cheaper compounds. The label is not false. It is structured to prevent verification.

The creatine literature is instructive here. EFSA's evaluation of the health claim application for creatine and cognitive function examined the evidence at specific doses and concluded that the evidence, while interesting, did not meet the threshold for an authorised claim at the time of evaluation. Turck 2024 The physical performance literature for creatine, by contrast, is substantially more robust — but it is robust at doses of 3-5g per day, not at the 200-500mg doses that appear in many multi-ingredient products. KōJō Daily Formula includes Creatine Monohydrate at 5000mg — the dose at which the performance evidence is strongest.

Similarly, the evidence base for Bacopa Monnieri in cognitive function is built primarily on trials using standardised extracts at doses of 300mg and above. KōJō includes Bacopa Monnieri Extract at 300mg. The evidence base for Rhodiola Rosea in stress-related fatigue is built on trials using doses in the range of 200-600mg of standardised extract. KōJō includes Rhodiola Rosea Extract at 350mg. These are not arbitrary numbers. They are the doses at which human trials have been conducted.

What KōJō Daily Formula Does for Standards & Transparency

KōJō Daily Formula v4.1 is a fully disclosed, single-serving daily formula. Every ingredient is listed with its exact dose. There are no proprietary blends. There is no "matrix" obscuring individual compound weights. The formulation is available for independent verification against the primary literature.

The following ingredients are included at doses consistent with the evidence base that informed their selection:

Creatine Monohydrate — 5000mg. The physical performance evidence for creatine is robust at this dose. EFSA has evaluated a health claim application for creatine and cognitive function; the physical performance evidence base is more established. Turck 2024

Vitamin C — 500mg. EFSA's NHC register approves the wording "Vitamin C contributes to normal collagen formation for the normal function of skin" and "Vitamin C contributes to the reduction of tiredness and fatigue." The 500mg dose is consistent with the range studied in human trials.

Algal DHA — 250mg. EFSA's NHC register approves the wording "DHA contributes to maintenance of normal brain function" and "DHA contributes to the maintenance of normal vision." Algal-sourced DHA is the form used in the trials on which these claims are based and is appropriate for individuals who do not consume oily fish.

Ubiquinol — 100mg. The reduced, bioavailable form of CoQ10. Formulation decisions prioritising bioavailability over cost are a transparency commitment, not a marketing one.

N-Acetyl Cysteine — 600mg. A precursor to glutathione, included at a dose consistent with the human trial literature on oxidative stress markers.

Alpha Lipoic Acid — 200mg. Included at a dose consistent with the human trial literature.

Rhodiola Rosea Extract — 350mg. Included at a dose within the range studied in RCTs examining stress-related fatigue.

Bacopa Monnieri Extract — 300mg. Included at the dose used in the human trials that form the primary evidence base for this ingredient.

Magnesium Bisglycinate — 1000mg (200mg elemental). Chelated form selected for bioavailability. EFSA's NHC register approves multiple health claims for magnesium including contributions to normal muscle function and reduction of tiredness and fatigue.

Zinc Bisglycinate — 53mg (16mg elemental). Chelated form selected for bioavailability. EFSA's NHC register approves health claims for zinc including contributions to normal cognitive function and normal immune system function.

Vitamin D3 — 50mcg. EFSA's NHC register approves the wording "Vitamin D contributes to the normal function of the immune system" and "Vitamin D contributes to the maintenance of normal bones." 50mcg (2000 IU) is within the range most commonly studied in UK adult populations, where insufficiency is prevalent.

Vitamin K2 MK-7 — 180mcg. The MK-7 form has a longer half-life than MK-4, supporting more consistent circulating levels. EFSA's NHC register approves the wording "Vitamin K contributes to normal blood clotting" and "Vitamin K contributes to the maintenance of normal bones."

Folate — 400mcg. Active methylfolate form, addressing the bioavailability issue associated with folic acid in individuals with MTHFR polymorphisms. Zhang 2025

Vitamin B12 — 500mcg. EFSA's NHC register approves the wording "Vitamin B12 contributes to normal energy-yielding metabolism" and "Vitamin B12 contributes to the normal function of the nervous system."

Glycine — 2000mg. A conditionally essential amino acid included at a dose consistent with the human trial literature on sleep quality and connective tissue support.

Taurine — 2000mg. Included at a dose consistent with the human trial literature.

Aged Garlic Extract — 600mg. The functional foods literature has examined garlic and its derivatives in the context of cardiovascular biomarkers. The evidence is more consistent for aged garlic extract than for raw garlic, and the 600mg dose reflects the range studied. Fekete 2025

Olive Leaf Extract — 500mg. Olive polyphenols have been examined in the context of cardiovascular health. The dose-specificity of polyphenol effects is well-documented in the olive oil literature. Mancebo-Campos 2023

Grape Seed Extract — 200mg. Included at a dose consistent with the human trial literature on oligomeric proanthocyanidins.

Pine Bark Extract — 150mg. Included at a dose consistent with the human trial literature.

Bacillus coagulans GBI-30, 6086 — 2 billion CFU. A strain-specific probiotic. The probiotic literature consistently demonstrates that strain identity and dose are the two most important determinants of effect — generic "probiotic" claims without strain specification are not evidence-based. Krumbeck 2019

Tributyrin — 500mg. A prodrug form of butyrate, included for its role in supporting intestinal barrier function.

Moringa Leaf Powder — 2500mg. Included as a whole-food micronutrient source. The evidence base for moringa is developing; this ingredient is included for its nutrient density profile rather than a specific isolated clinical claim.

Choline Bitartrate — 1000mg. EFSA's NHC register approves the wording "Choline contributes to normal lipid metabolism" and "Choline contributes to the maintenance of normal liver function."

L-Theanine — 200mg. Included at the dose most commonly used in human trials examining attention and relaxation without sedation, typically in combination with caffeine. KōJō's Matcha Green Tea Powder at 2000mg provides a natural source of both L-theanine and caffeine.

Selenium — 100mcg. EFSA's NHC register approves the wording "Selenium contributes to the normal function of the thyroid gland" and "Selenium contributes to the maintenance of normal hair and nails."

Iodine — 150mcg. EFSA's NHC register approves the wording "Iodine contributes to normal thyroid function" and "Iodine contributes to normal cognitive function."

The remaining micronutrients — Vitamin A (750mcg RAE), Vitamin E (15mg), Vitamin B1 (2.2mg), Vitamin B2 (2.8mg), Vitamin B3 (500mg), Vitamin B5 (6mg), Vitamin B6 (2.8mg), Biotin (100mcg), Chromium (200mcg), Copper (2mg), Manganese (2mg), Molybdenum (75mcg) — are included at doses consistent with or above the EU Nutrient Reference Values, with EFSA-authorised health claims supporting their inclusion.

The functional ingredients — MCT Powder (1500mg), Ginger Root Extract (500mg), Yuzu Powder (250mg), Japanese Green Plum Powder (300mg), Himalayan Pink Salt (1000mg), Potassium Chloride (300mg) — are included for their nutritional and palatability contributions. Ginger's evidence base in the context of gastrointestinal comfort is reasonably well-developed in the human trial literature. Fekete 2025

Standards and transparency are not a positioning strategy. They are what the category owes anyone who takes it seriously. The supplement industry has spent decades building a reputation for opacity, overclaiming, and selective citation. The response to that is not cynicism about the entire category — it is demanding better, knowing what to look for, and holding manufacturers to the same evidentiary standards you would apply to any other health decision.

That is what this guide is for.

Frequently Asked Questions